Daiichi Sankyo Returns HGF Gene Therapy U.S. And European Rights To AnGes MG
This article was originally published in PharmAsia News
Executive Summary
AnGes MG announced that Daiichi Sankyo, a collaborating partner under an exclusive marketing agreement to develop a gene therapy consisting of plasmid HGF to treat peripheral arterial disease and ischemic heart disease, decided to return the exclusive marketing rights in the U.S. and Europe to AnGes. Daiichi Sankyo will keep the rights in Japan and the two companies still plan to collaborate on launching the drug upon obtaining an approval. An NDA for the plasmid HGF Collategene was filed in Japanin March, 2008. In the U.S. and Europe, AnGes plans to initiate a Phase III trial this year. (Click here for more - Japanese language